India is widely known as the “pharmacy of the world,” but not every medicine can be bought as a cheap generic on day one. If a drug is still under patent, even the world’s largest generic manufacturers cannot legally produce it — and this is why your favourite low-cost version of a medicine often appears years after the brand-name version. Understanding how patents shape generic market-entry timing is essential for any international buyer sourcing Indian generic medicines. This guide explains how patents work, why generic entry happens at different times in different countries, and how you can time your purchasing decisions around patent expiry.
📜 What Are Drug Patents — and Why Do They Delay Cheaper Generics?
A patent is a legally enforced exclusive right granted to an inventor for a limited period, typically 20 years from the filing date under the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement. During the patent term, only the patent holder — or firms it licenses — may make, sell, or import the patented active ingredient. Because competition is excluded, the patent holder can keep prices high.
Once the patent expires, the active ingredient enters the public domain, and generic manufacturers are free to produce identical versions. This is why the arrival of generics reliably forces prices down. For buyers, the practical question is always: when does the patent on this medicine expire — and has it expired in the market where I am buying it?
⏳ How Generic Market-Entry Timing Works: Patents, Exclusivity, and Geography
Generic entry is rarely a single global event. Because patents are national rights, a medicine can go generic in one country while remaining under patent in another. Several factors drive the staggered timing:
- Country-by-country patents — an originator may file and win patents in some markets and not others, so expiry dates differ by country. The semaglutide patent expired in India in March 2026 but remains protected in several other markets.
- Data and regulatory exclusivity — even after a patent expires, regulators may grant separate periods of data exclusivity that prevent a generic from referencing the innovator’s clinical data. The Hindu reported in November 2025 that activists warn such exclusivity periods “extend pharma monopolies” and delay access to affordable medicines.
- Regulatory approval — a generic cannot be sold until it passes its own approval (in India, CDSCO approval for the specific product). Patent expiry and regulatory approval are two separate gates, and both must open before launch.
The result is that the cheapest window to buy a given generic usually appears in emerging markets first, and only reaches the US and Europe later. Buyers who understand this can source affordably from markets where patents have already lapsed.
🇮🇳 India’s 2005 Patent Shift — and Its Pro-Generic Position
Until the mid-1990s, India did not grant product patents on pharmaceutical substances. This meant local firms could legally reverse-engineer and produce cheap copies of medicines patented elsewhere, which is how India became the pharmacy of the developing world. To comply with its TRIPS obligations, India reintroduced product patents from 1 January 2005 through an amendment to its Patents Act, 1970.
Yet India kept several safeguards that favour generic competition:
- Section 3(d) — a widely debated provision designed to prevent “evergreening,” under which trivial modifications of a known medicine are refused new patents.
- Mandatory (compulsory) licensing — India’s law allows the government to authorise a third party to produce a patented medicine in defined public-interest situations. India granted its first compulsory licence in 2012 for the Bayer cancer drug sorafenib (Nexavar), as reported by Intellectual Property Watch.
Bar and Bench reported in March 2026 that Indian law enables affordable medicine production without violating patent law, reinforcing India’s position as a manufacturing base for affordable generics. [CITATION NEEDED: exact Section 3(d) case outcomes and any 2026 revisions to these provisions.]
💊 Case Study: The Semaglutide Patent Expiry of March 2026
The clearest recent example of how patent expiry unlocks generic entry is semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy. When the semaglutide patent expired in India in March 2026, Indian manufacturers moved quickly to launch cheaper generic versions. Reuters reported on 19 March 2026 that the “Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India.”
- Scale of entry — NDTV and NAVLIN DAILY reported in early March 2026 that 50+ branded semaglutide generics were set to enter India as the patent lapsed.
- Price impact — Bloomberg reported on 21 March 2026 that Ozempic-style copies could cost about $14 in India as the generic GLP-1 era began, versus far higher prices in markets still under exclusivity.
- Global significance — BBC (17 March 2026) and The New York Times (30 March 2026) framed India’s cheap semaglutide generics as potentially reshaping the global obesity and diabetes treatment market. CNN (February 2026) asked whether India was about to make weight-loss drugs “a whole lot cheaper.”
- Legal battles continue — medwatch reported on 6 May 2026 that Novo Nordisk was taking legal action after the patent’s expiration in India, a reminder that contested patents can create uncertainty even after expiry.
Lesson for buyers: a confirmed patent expiry in the Indian market — combined with CDSCO approval — is the trigger point at which affordable Indian generics become legally available and prices drop sharply.
🧬 Biosimilars and Biologics: A Different Entry Timeline
Large-molecule biological medicines do not have “generic” copies; they have biosimilars. A biosimilar is a biological product shown to be highly similar to an already-approved reference biologic, with no clinically meaningful differences. Because biologics are far more complex than small-molecule pills, biosimilar entry usually takes longer, costs more to develop, and requires more demanding regulatory review (comparability and clinical data).
This is why an expiring patent on a complex biologic does not translate into dozens of instant cheap copies the way it does for a small-molecule drug like semaglutide. For biosimilars, buyers should evaluate each manufacturers’ regulatory approvals (for example, CDSCO approval in India or US FDA approval) rather than assuming a patent lapse alone signals availability.
📊 The 2026 Patent Cliff — and What It Means for Buyers
2026 is a significant year for patent expirations. Drug Discovery News reported in February 2026 that blockbuster drugs face a “massive patent cliff in 2026,” and Fierce Pharma (March 2026) published a roundup of the top drugs losing US exclusivity in 2026. For Indian manufacturers, this is a growth opportunity: Business Standard reported in June 2026 that patent expiry represents a USD 5 billion opportunity for Indian pharma majors.
For international buyers, the 2026 patent cliff means a fresh wave of affordable generics will become available in India and other early-expiry markets over the year — from GLP-1 diabetes and weight-loss drugs to oncology and immunology therapies. The key is to identify which products are actually approved in India and to source them through verified channels.
✅ Buyer’s Checklist: Timing Your Purchase of Indian Generics
- Confirm patent status in your target market — generics legal in India may still be protected where you import them; understand the rules in your own country first.
- Wait for both gates — verify the patent has lapsed AND that the specific product has CDSCO approval before treating a generic as available.
- Watch for the brand wave — when many manufacturers launch simultaneously (as with semaglutide’s 50+ brands), prices typically fall fast and supply is plentiful.
- Distinguish authorised generics from counterfeit products — a flood of new brands also raises the risk of unlicensed copies; always buy documented, regulator-approved products.
- For biologics, check biosimilar equivalence, not simply patent status — confirm the manufacturer’s CDSCO/FDA approval for the specific product.
- Verify the manufacturer and importer — cross-check the CDSCO manufacturing licence, batch records, and certificates before committing.
- Buy through verified distributors — for a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
🔮 Final Thoughts
Patents, not production capacity, are usually what delay affordable generic medicines. Because patents are country-specific, the most affordable source of a recently expired drug is often an emerging market like India — but only once the patent has lapsed and the product has cleared regulatory approval in that market. The 2026 semaglutide story shows just how quickly prices collapse when both conditions are met.
By learning to read patent and exclusivity timelines, international buyers can source Indian generics at the right moment — at far lower cost and with the same quality assurance. To work with distributors you can trust, consult the list of IMSDA member distributors before placing orders.
📋 Sources
- Reuters — “Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India” (March 2026)
- Bloomberg — “Ozempic Copies to Cost $14 in India as Generic GLP-1 Era Starts” (March 2026)
- BBC — “Ozempic, Wegovy: India’s cheap weight-loss drugs could reshape global obesity fight” (March 2026)
- The New York Times — “Ozempic Is About to Go Generic for Billions of People” (March 2026)
- CNN — “Is India about to make Ozempic-like weight-loss drugs a whole lot cheaper?” (February 2026)
- Fierce Pharma — “With Novo’s semaglutide going off patent, Indian drugmakers set to launch their cheaper generics” (March 2026)
- NDTV / NAVLIN DAILY — “50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026” (March 2026)
- STAT / Chemistry World — coverage of India’s generic semaglutide surge (March–April 2026)
- medwatch — “Novo Nordisk takes legal action after patent expiration in India” (May 2026)
- Drug Discovery News — “Blockbuster drugs face a massive patent cliff in 2026” (February 2026)
- Fierce Pharma — “The top 10 drugs losing US exclusivity in 2026” (March 2026)
- Business Standard — “Patent expiry: A $5 bn opportunity for Indian pharma majors, says report” (June 2026)
- The Hindu — “Data exclusivity will extend pharma monopolies, delay access to affordable medicines” (November 2025)
- Bar and Bench — “Patient versus patent: How Indian law enables affordable medicine production without patent law violation” (March 2026)
- Intellectual Property Watch — “India Grants First Compulsory Licence, For Bayer Cancer Drug” (March 2012)
For more information, contact IMSDA at contact@indiamedicine.org.